PaxMedica Inc. (NASDAQ: PXMD) Is ‘One to Watch’
PaxMedica recently announced positive top line results from its PAX-101 Phase 3 African Sleeping Sickness Study, paving the way for an expected New Drug Application filing in 2024 The company granted exclusive pharmacy distribution for PAX-101 to Vox Nova LLC, the first purpose-built limited distribution specialty pharmacy benefit manager for people with ASD PaxMedica submitted PAX-101 Clinical Trial Request to the South African Health Products Regulatory Authority, requesting approval for a double-blind, placebo-controlled study in ASD The company entered a Research Collaboration Agreement with PoloMar Health and The BRAIN Foundation for a Phase II proof-of-concept trial in ASD PaxMedica (NASDAQ:…